Theracryf Plc

Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II clinical trials for metastatic breast cancer. Additionally, SFX-01 is in Phase I trials for neurodevelopmental conditions and glioblastoma, and is undergoing preclinical investigation for rhabdomyosarcoma. The company's pipeline also includes an orexin 1 antagonist, which is in the late preclinical stage for addressing addiction and anxiety, alongside an atypical dopamine transporter inhibitor (DAT) at a similar development stage, targeting fatigue and narcolepsy. Incorporated in 2014 and headquartered in Nether Alderley, United Kingdom, the company rebranded from Evgen Pharma plc to Theracryf Plc in April 2024.

Theracryf Plc trades as TCF.L on LSE. The company is classified in Healthcare / Biotechnology and reports in GBP.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Theracryf Plc can be compared against peers such as Chill Brands Group PLC, CRISM Therapeutics Corporation, Feedback plc, MyHealthChecked PLC, N4 Pharma Plc, Oxford BioDynamics Plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £4.94M, beta of 1.40, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

TCF.L currently shows total debt of N/A and beta of 1.40. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://theracryf.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.